Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMNFree Report) by 15.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 287,470 shares of the life sciences company’s stock after selling 52,284 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Illumina were worth $39,464,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Illumina during the 3rd quarter valued at about $29,558,000. Van ECK Associates Corp grew its position in Illumina by 1.7% in the 2nd quarter. Van ECK Associates Corp now owns 112,444 shares of the life sciences company’s stock worth $21,082,000 after purchasing an additional 1,861 shares during the last quarter. Weil Company Inc. grew its position in Illumina by 59.2% in the 3rd quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock worth $3,152,000 after purchasing an additional 8,539 shares during the last quarter. Harvest Fund Management Co. Ltd grew its position in Illumina by 60.6% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,246 shares of the life sciences company’s stock worth $171,000 after purchasing an additional 470 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in Illumina in the 2nd quarter worth about $27,186,000. Institutional investors own 92.17% of the company’s stock.

Illumina Stock Down 3.8 %

Shares of NASDAQ:ILMN opened at $137.84 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.28 and a current ratio of 1.69. The company has a market cap of $21.89 billion, a PE ratio of -18.78, a price-to-earnings-growth ratio of 25.82 and a beta of 1.22. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $238.55. The firm has a 50 day simple moving average of $135.24 and a 200 day simple moving average of $138.32.

Illumina (NASDAQ:ILMNGet Free Report) last issued its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.15%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.14 EPS. As a group, research analysts expect that Illumina, Inc. will post 1.04 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on ILMN. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Wednesday. Wolfe Research began coverage on shares of Illumina in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $175.00 target price for the company. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Guggenheim assumed coverage on shares of Illumina in a report on Thursday, December 14th. They issued a “buy” rating and a $155.00 price objective for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $258.00 price objective on shares of Illumina in a report on Friday. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $166.95.

View Our Latest Stock Analysis on ILMN

Illumina Company Profile

(Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Read More

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.